Advances in the Management of Anal Cancer

Diana R. Julie; Karyn A. Goodman

doi:10.1007/s11912-016-0503-3

Advances in the Management of Anal Cancer

Diana R. Julie, Karyn A. Goodman

Research output: Contribution to journal › Review article › peer-review

20 Scopus citations

Abstract

Although anal squamous cell carcinoma (ASCC) is an uncommon malignancy, its incidence has been increasing markedly in recent decades due to its association with human papilloma virus (HPV) infection. The well-established standard of care for localized ASCC consists of the combination of 5-fluorouracil (5FU) and mitomycin (MMC) chemotherapy, concurrent with external beam radiation therapy (EBRT). However, newer techniques are being actively pursued, including the use of newer radiation therapy (RT) technologies, such as intensity-modulated radiation therapy (IMRT). The areas of debate and development include the dosing and timing of MMC delivery, the role of cisplatin chemotherapy as an alternative to MMC, the replacement of the standard 96-h infusion of 5FU with oral capecitabine, the use of targeted chemotherapy agents, and the duration and dose of RT.

Original language	English
Article number	20
Pages (from-to)	1-12
Number of pages	12
Journal	Current Oncology Reports
Volume	18
Issue number	3
DOIs	https://doi.org/10.1007/s11912-016-0503-3
State	Published - 1 Mar 2016
Externally published	Yes

Keywords

Anal cancer
Definitive chemoradiation
Human papilloma virus
Intensity-modulated radiotherapy
Squamous cell carcinoma

Access to Document

10.1007/s11912-016-0503-3

Cite this

@article{ec96d95b1a8c4a2fb39b6a6843602b1a,

title = "Advances in the Management of Anal Cancer",

abstract = "Although anal squamous cell carcinoma (ASCC) is an uncommon malignancy, its incidence has been increasing markedly in recent decades due to its association with human papilloma virus (HPV) infection. The well-established standard of care for localized ASCC consists of the combination of 5-fluorouracil (5FU) and mitomycin (MMC) chemotherapy, concurrent with external beam radiation therapy (EBRT). However, newer techniques are being actively pursued, including the use of newer radiation therapy (RT) technologies, such as intensity-modulated radiation therapy (IMRT). The areas of debate and development include the dosing and timing of MMC delivery, the role of cisplatin chemotherapy as an alternative to MMC, the replacement of the standard 96-h infusion of 5FU with oral capecitabine, the use of targeted chemotherapy agents, and the duration and dose of RT.",

keywords = "Anal cancer, Definitive chemoradiation, Human papilloma virus, Intensity-modulated radiotherapy, Squamous cell carcinoma",

author = "Julie, \{Diana R.\} and Goodman, \{Karyn A.\}",

note = "Publisher Copyright: {\textcopyright} 2016, Springer Science+Business Media New York.",

year = "2016",

month = mar,

day = "1",

doi = "10.1007/s11912-016-0503-3",

language = "English",

volume = "18",

pages = "1--12",

journal = "Current Oncology Reports",

issn = "1523-3790",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - Advances in the Management of Anal Cancer

AU - Julie, Diana R.

AU - Goodman, Karyn A.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Although anal squamous cell carcinoma (ASCC) is an uncommon malignancy, its incidence has been increasing markedly in recent decades due to its association with human papilloma virus (HPV) infection. The well-established standard of care for localized ASCC consists of the combination of 5-fluorouracil (5FU) and mitomycin (MMC) chemotherapy, concurrent with external beam radiation therapy (EBRT). However, newer techniques are being actively pursued, including the use of newer radiation therapy (RT) technologies, such as intensity-modulated radiation therapy (IMRT). The areas of debate and development include the dosing and timing of MMC delivery, the role of cisplatin chemotherapy as an alternative to MMC, the replacement of the standard 96-h infusion of 5FU with oral capecitabine, the use of targeted chemotherapy agents, and the duration and dose of RT.

AB - Although anal squamous cell carcinoma (ASCC) is an uncommon malignancy, its incidence has been increasing markedly in recent decades due to its association with human papilloma virus (HPV) infection. The well-established standard of care for localized ASCC consists of the combination of 5-fluorouracil (5FU) and mitomycin (MMC) chemotherapy, concurrent with external beam radiation therapy (EBRT). However, newer techniques are being actively pursued, including the use of newer radiation therapy (RT) technologies, such as intensity-modulated radiation therapy (IMRT). The areas of debate and development include the dosing and timing of MMC delivery, the role of cisplatin chemotherapy as an alternative to MMC, the replacement of the standard 96-h infusion of 5FU with oral capecitabine, the use of targeted chemotherapy agents, and the duration and dose of RT.

KW - Anal cancer

KW - Definitive chemoradiation

KW - Human papilloma virus

KW - Intensity-modulated radiotherapy

KW - Squamous cell carcinoma

UR - https://www.scopus.com/pages/publications/84975701698

U2 - 10.1007/s11912-016-0503-3

DO - 10.1007/s11912-016-0503-3

M3 - Review article

C2 - 26905274

AN - SCOPUS:84975701698

SN - 1523-3790

VL - 18

SP - 1

EP - 12

JO - Current Oncology Reports

JF - Current Oncology Reports

IS - 3

M1 - 20

ER -

Advances in the Management of Anal Cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this